PMID- 33878875
OWN - NLM
STAT- MEDLINE
DCOM- 20211112
LR  - 20211112
IS  - 1735-3947 (Electronic)
IS  - 1029-2977 (Linking)
VI  - 24
IP  - 3
DP  - 2021 Mar 1
TI  - Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to 
      Targeted Screening.
PG  - 177-186
LID - 10.34172/aim.2021.28 [doi]
AB  - BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is common in people with 
      type 2 diabetes mellitus (T2DM). We aimed to explore predictive factors of NAFLD 
      in T2DM and identify high risk subgroups. METHODS: This was a cross-sectional 
      study including 100 individuals with T2DM and 100 without diabetes matched for 
      age, sex, and body mass index (BMI). Hepatic steatosis grades (calculated by 
      controlled attenuation parameters-CAP score-3), and liver fibrosis stages (F0-F4) 
      were determined using transient elastography. RESULTS: The frequency of NAFLD was 
      comparable between the two study groups. However, CAP scores were significantly 
      higher in individuals with diabetes (294.90 +/- 53.12 vs. 269.78 +/- 45.05 dB/m; P < 
      0.001). Fifty percent of individuals with diabetes had severe steatosis (S3), 
      while this figure was 31.6% in those without diabetes (P < 0.05). Significant 
      fibrosis (F2-F4) was more frequent in individuals with T2DM (13% vs. 4.1%, P = 
      0.02). Individuals with T2DM and advanced fibrosis had significantly higher BMI, 
      waist circumference (WC), waist-hip ratio (WHR), alanine aminotransferase (ALT), 
      aspartate aminotransferase (AST), and CAP score compared to those without 
      fibrosis (P < 0.05). In the regression analysis, a model including BMI, WHR, AST 
      and female gender explained 50% of the variation in CAP score in patients with 
      diabetes (all P < 0.05, adjusted R(2) : 0.508). CAP scores were also the major 
      determinant of liver fibrosis in this group (OR: 1.04; CI: 1.017-1.063; P = 
      0.001). CONCLUSION: Individuals with diabetes are more likely to have severe 
      fibrosis. Obesity (especially central obesity), the female gender, elevated liver 
      enzymes, and higher degree of insulin resistance are associated with more 
      advanced liver disease in individuals with T2DM.
CI  - (c) 2021 The Author(s). This is an open-access article distributed under the terms 
      of the Creative Commons Attribution License 
      (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, 
      distribution, and reproduction in any medium, provided the original work is 
      properly cited.
FAU - Poustchi, Hossein
AU  - Poustchi H
AD  - Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research 
      Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Alaei-Shahmiri, Fariba
AU  - Alaei-Shahmiri F
AD  - Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran 
      University of Medical Sciences, Tehran, Iran.
FAU - Aghili, Rokhsareh
AU  - Aghili R
AD  - Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran 
      University of Medical Sciences, Tehran, Iran.
FAU - Nobarani, Sohrab
AU  - Nobarani S
AD  - Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran 
      University of Medical Sciences, Tehran, Iran.
FAU - Malek, Mojtaba
AU  - Malek M
AD  - Research Center for Prevention of Cardiovascular Disease, Institute of 
      Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
FAU - Khamseh, Mohammad E
AU  - Khamseh ME
AD  - Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran 
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20210301
PL  - Iran
TA  - Arch Iran Med
JT  - Archives of Iranian medicine
JID - 100889644
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - IM
MH  - Adult
MH  - Alanine Transaminase/blood
MH  - Aspartate Aminotransferases/blood
MH  - Body Mass Index
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Elasticity Imaging Techniques
MH  - Female
MH  - Humans
MH  - Insulin Resistance
MH  - Liver Cirrhosis/*diagnosis/diagnostic imaging
MH  - Male
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/*diagnosis/diagnostic imaging
MH  - Obesity, Abdominal/*complications
MH  - Regression Analysis
MH  - Risk Factors
MH  - Sex Factors
MH  - Waist Circumference
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Hepatic steatosis
OT  - Liver fibrosis
OT  - NAFLD
OT  - Non-alcoholic fatty liver disease
OT  - Type 2
EDAT- 2021/04/22 06:00
MHDA- 2021/11/16 06:00
CRDT- 2021/04/21 05:30
PHST- 2020/04/20 00:00 [received]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2021/04/21 05:30 [entrez]
PHST- 2021/04/22 06:00 [pubmed]
PHST- 2021/11/16 06:00 [medline]
AID - 10.34172/aim.2021.28 [doi]
PST - epublish
SO  - Arch Iran Med. 2021 Mar 1;24(3):177-186. doi: 10.34172/aim.2021.28.